𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma?

✍ Scribed by Víctor Hugo Jimenez-Zepeda; Virginia Jeanet Domínguez-Martínez

Book ID
114794057
Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
619 KB
Volume
77
Category
Article
ISSN
0902-4441

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II clinical trial of arsenic triox
Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma
✍ C.C. Hofmeister; B. Jansak; N. Denlinger; E.H. Kraut; D.M. Benson; S.S. Farag 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 90 KB

In patients with multiple myeloma, there is preclinical justification to combine arsenic trioxide (ATO and As 2 O 3 ) with DVd (Doxil TM , vincristine, and dexamethasone) for newly diagnosed patients. Eleven patients on this phase II trial received 0.15 mg/kg of ATO for five consecutive days followe

Bortezomib in combination with dexametha
Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: A Chinese experience
✍ Weiyan Zheng; Guoqing Wei; Xiujin Ye; Jingsong He; Li Li; Wenjun Wu; Jimin Shi; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 245 KB

## Objective: Bortezomib-dexamethasone-thalidomide has been reported to be effective in newly-diagnosed multiple myeloma (mm) with an overall response rate of 92% and a cr rate of 18% (alexanian et al, hematology 2007;12(3):235-9), but this regimen has not been tested in the chinese patients. we re